Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Kevin Kotler & Broadfin Capital Take a 5.2% Stake in Biodel

Biodel, Broadfin Capital: In a 13G filing reported a few minutes ago, Kevin Kotler‘s Broadfin Capital disclosed ownership of a 5.2% stake in Biodel Inc (NASDAQ:BIOD), a company engaged in the development of diabetes treatments. Broadfin is a hedge fund almost entirely focused in healthcare, with the majority of its $500 million equity portfolio invested in this space.

Kevin Kotler

At the beginning of September, Biodel disclosed positive news on its BIOD-123 phase 2 clinical study. BIOD-123 is “an investigational ultra-rapid-acting mealtime insulin, in patients with type 1 diabetes,” which “achieved the primary endpoint of non-inferiority for HbA1c relative to insulin lispro, a widely prescribed rapid acting mealtime insulin analog marketed as Humalog® ,” Biodel said in a statement.

In the third fiscal quarter, Biodel posted a net loss of $9.6 million, equal to $0.66 per share, expanding it from the $6.1 million net loss posted for the same three months of 2012.

Samuel Isaly‘s Orbimed Advisors helds the largest stake in Biodel, out of the funds we track. Its position contains almost 2.7 million shares.

Disclosure: none

Recommended Reading:

Nevada Capital Cuts Genco Shipping & Trading Significantly

Heartland Advisors Discloses a 1.9% Stake in Lantronix

Fort Dearborn Receives Vote of Confidence From Karpus Management


DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.